Friday 6 November 2026
Export TDOC’s income statement to Excel — free account
Teladoc Health, Inc.
TDOC Healthcare Health Information Services
Teladoc Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, down 1.54% from fiscal 2024.
- Revenue
- −3.41%
- EPS
- +47.1%
- Free cash flow
- +11.8%
- Total debt
- +0.36%
Quarter to September 2026, against a year earlier
8.78
0.63
−6.70%
Follow TDOC
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.49 | 0.39 | 0.62 | 0.43 | |
P/FCF ratio |
8.98 | 7.71 | 17.33 | 8.36 | |
P/Operating CF |
14.06 | 102.59 | 23.74 | 9.91 | |
P/B ratio |
0.89 | 0.73 | 1.17 | 0.81 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.79 | 0.70 | 1.11 | 0.89 | |
EV/EBITDA |
10.79 | 9.38 | 13.51 | 10.23 | |
EV/Operating CF |
6.79 | 6.15 | 10.54 | 8.19 | |
EV/FCF |
14.55 | 13.99 | 31.09 | 17.43 | |
Quick Ratio |
2.41 | 2.38 | 0.72 | 0.76 | |
Current Ratio |
2.77 | 2.80 | 0.83 | 0.87 | |
Net Debt/EBITDA |
3.38 | 7.56 | 4.02 | 2.31 | |
Debt/Assets |
34.81% | 35.47% | 36.13% | 35.95% | |
Debt/Equity |
0.72 | 0.75 | 0.76 | 0.77 | |
Asset Turnover |
0.79 | 0.80 | 0.88 | 0.87 | |
Operating CF/Net income |
(3.49) | (0.15) | (1.66) | (3.95) | |
Capex/Depreciation |
(0.35) | (0.38) | (0.45) | (0.33) | |
Interest Coverage |
(7.27) | (11.51) | (7.26) | (5.69) | |
Research and Development Expense of Revenue |
11.15% | 11.06% | 10.36% | 10.83% | |
Selling, General and Administrative Expense of Revenue |
47.60% | 49.67% | 48.90% | 46.43% | |
Intangible Assets out of Total Assets |
0.55 | 0.54 | 0.53 | 0.50 | |
Share Based Compensation of Revenue |
2.48% | 2.38% | 1.53% | 1.92% | |
Graham Net Nets |
(0.29) | (0.35) | (0.20) | (0.24) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(16.29%) | (17.80%) | (11.67%) | (14.79%) | |
Free Cash Flow Yield |
11.13% | 12.98% | 5.77% | 11.96% | |
Revenue per Share |
3.64 | 3.43 | 3.35 | 3.33 | |
Operating CF per Share |
0.50 | 0.05 | 0.36 | 0.59 | |
Capex per Share |
(0.19) | (0.20) | (0.23) | (0.17) | |
Free Cash Flow per Share |
0.30 | (0.15) | 0.13 | 0.42 | |
Cash per Share |
4.43 | 4.19 | 4.28 | 4.67 | |
Shareholders Equity per Share |
7.86 | 7.46 | 7.24 | 7.12 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.86 | 7.46 | 7.24 | 7.12 | |
Free Cash Flow |
53.42 | (26.31) | 23.07 | 75.94 | |
Working Capital |
714.39 | 727.47 | (233.37) | (189.49) | |
Capital Expenditures |
(34.32) | (35.82) | (41.59) | (30.52) | |
Net Current Asset Value |
(353.46) | (338.61) | (300.16) | (254.34) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.06 | 0.07 | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
203.49 | 223.30 | 223.22 | 220.85 | |
Average Payables |
40.55 | 48.63 | 45.97 | 49.27 | |
Average Inventory |
38.17 | 34.78 | 33.49 | 35.33 | |
Average Assets |
3,187.41 | 3,125.85 | 2,826.31 | 2,826.81 | |
Average Common Equity |
1,438.39 | 1,381.67 | 1,366.12 | 1,343.42 |
Columns are period end dates · fundamentals updated 2 Nov 2026